Please assess the completion status of the following clinical trial:

Trial Title: A Relative Bioavailability Study of Selpercatinib (LY3527723) in Healthy Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, and vital signs~* Body mass index (BMI) within the range 18.0 to 35.0 kilograms per meter squared (kg/m²)~Exclusion Criteria:~* Have a history of allergic reactions to medications or food products~* Have a clinically significant abnormality of blood pressure and/or pulse rate as determined by the investigator~* Clinically significant abnormalities on ECG as determined by the investigator or prolongation of the QTcB or QTcF \>450 msec at screening~* Have clinically significant active cardiovascular disease or history of myocardial infarction within 6 months prior to the planned start of selpercatinib~* Have a history or presence of cardiovascular, respiratory, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the investigational product; or of interfering with the interpretation of data. Appendectomy, splenectomy, and cholecystectomy are considered as acceptable~* Use of H2 blockers, proton pump inhibitors, and other drugs that affect selpercatinib exposure within 7 days of screening~* Are intending to use over-the-counter or prescription medication, including dietary supplements, within 14 days prior to dosing and until study discharge (apart from occasional acetaminophen (≤2 g/24 hours), hormonal contraception, or hormone replacement therapy)

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Selpercatinib (Formulation 1) (Type: EXPERIMENTAL): Selpercatinib (formulation 1) given orally on days 1, 8 or 15.
- Selpercatinib (Formulation 2) (Type: EXPERIMENTAL): Selpercatinib (formulation 2) given orally on days 1, 8 or 15.
- Selpercatinib (Formulation 3) (Type: EXPERIMENTAL): Selpercatinib (formulation 3) given orally on days 1, 8 or 15.

Based on this trial design, predict the completion outcome and termination type (if applicable).